Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Healthcare is timely and personal – and its delivery should be too
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Subscribe To Our Newsletter & Stay Updated
